In a new study, a team of scientists reveals evidence showing that the most prominent Alzheimer's disease risk gene may disrupt a fundamental process in a key type of brain cell. Moreover, in a sign of how important it is to delve into the complex ways that genes intersect in disease, they found that increasing the expression of another Alzheimer's-associated gene in those cells could help alleviate the problem.
About 25 percent of people have the APOE4 variant of the APOE gene, which puts them at substantially greater risk for Alzheimer's disease than those with the more common APOE3 version. Scientists have been working for decades to understand why this is so. The new study in Cell Reports finds that in astrocytes, which are the most common non-neuron cell in the brain, the variant hampers the process of endocytosis, which is a major way that cells bring materials in from outside. That functional deficit could undermine several of the vital roles that astrocytes play in the brain, the researchers noted, including how they facilitate communication among neurons or maintain the blood-brain barrier, which stringently filters what circulates into or out of the brain.
"We have identified that APOE4 imposes an endocytosis deficiency in astrocytes," said the study's corresponding author. "This effect could have a number of downstream consequences such as impaired communication with other cell types, poor clearance of extracellular material, or poor maintenance of metabolic homeostasis."
As part of their work, the team also found that in APOE4-carrying astrocytes increasing expression of an Alzheimer's associated gene called PICALM reversed the endocytosis defects.
"Both APOE and PICALM are Alzheimer's risk genes," said the author. "It is really interesting that the two genes converge on endocytosis. This indicates that faulty endocytosis plays a key role in the etiology of Alzheimer's."
For at least a decade, studies have suggested connections among Alzheimer's, APOE4 and errant endocytosis, but have not pinpointed specific mechanisms. The team sought them out--and also looked for ways to remediate the deficits--through a series of lab experiments in cultures of stem cell-derived human astrocytes and genetically engineered yeast. The team focused on astrocytes because they produce the most ApoE protein in the brain.
By comparing astrocytes that were identical except in whether they had the APOE4 or APOE3 variants, the researchers found several signs of disrupted endocytosis, specifically in the early stage of the process when key proteins were notably reduced in the APOE4 carrying cells. They were able to directly observe that the afflicted astrocytes were less capable of bringing in materials from the outside. When they knocked out the APOE gene they no longer saw a defect in early endocytosis, affirming that the problem related to having the APOE4 variant.
By engineering human APOE3 and APOE4 into yeast cells, the team was able to replicate clear signs of APOE4's early endocytic disruption. This is possible because the function is so fundamental to how cells work, it is similar, or "conserved," in yeast and people. Once they knew they could use yeast as a model, they could then set out to look for endocytosis proteins that, if manipulated, could rescue the observed defect. They found one: a yeast protein called Yap1802p. When they made the yeast cells express extra Yap1802p, early endocytosis proteins were produced at normal levels, endocytosis function operated better and APOE4 cells, which had failed to grow as healthfully as APOE3 cells did, exhibited better growth.
Importantly, the gene that encodes Yap1802p has a human counterpart: PICALM. Studies have shown PICALM to have a complex but significant role in affecting Alzheimer's disease risk.
With their promising results in yeast, the researcher team returned to their human astrocyte cultures. Overexpressing PICALM in APOE4 astrocytes repaired early endocytosis function, as measured by the increased intake of test proteins. But they also saw that overexpressing PICALM in APOE3 astrocytes caused an endocytosis defect, illustrating that the effects of PICALM varies markedly in astrocytes based on APOE variant.
Although, it is difficult to find drugs that specifically increase endocytosis, this study could help scientists and clinicians better understand patients' risk, the author said.
"In our study, we see that in the context of an APOE4 genotype, increasing PICALM can alleviate deficiencies in early endocytosis," the author said. "Given that APOE4 carriers represent a significant proportion of AD patients, this functional interaction between APOE4 and PICALM could be relevant to assessing their level of disease risk. It also gives an example of how the genetic background of an individual can interact and potentially modulate the detrimental effects of the APOE4 genotype."
Moreover, the team's method of going back and forth between human cell cultures and yeast, provides a way of identifying how AD risk genes impact cellular biology, and how other genes can modulate these effects.
https://www.cell.com/cell-reports/fulltext/S2211-1247(20)31213-4
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fpicalm-rescues&filter=22
Rescuing endocytosis defect in Alzheimer's disease
- 1,382 views
- Added
Edited
Latest News
A new gene-editing system
By newseditor
Posted 23 May
How ketamine's molecular ac…
By newseditor
Posted 23 May
Therapeutic avenues in bone…
By newseditor
Posted 23 May
Linking key nutrients with…
By newseditor
Posted 23 May
Ferroptosis in fatal COVID-…
By newseditor
Posted 22 May
Other Top Stories
Mitochondrial connection to inflammation
Read more
Anti-inflammatory immune cells are maturing into wrong cell type in…
Read more
Linking neurodegeneration and immune cells
Read more
Pro-oxidants may fix metabolic defect in arthritis-driving T cells
Read more
Bone regeneration following injury!
Read more
Protocols
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Publications
Patterning and folding of i…
By newseditor
Posted 23 May
Peri-ictal activation of do…
By newseditor
Posted 23 May
Ancestry, ethnicity, and ra…
By newseditor
Posted 23 May
Ketamine can produce oscill…
By newseditor
Posted 23 May
Upregulation of neuronal ER…
By newseditor
Posted 23 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar